showed reduced fat mass with adipocyte hypertrophy and insulin resistance, which were highly predictable from known actions of PPARg agonists and phenotypes of patients with the PPARg mutation. This report is the first in our knowledge to clearly demonstrate that both alleles of PPARg are required for normal adipocyte development and insulin sensitivity in vivo. Furthermore, the study indicates that PPARg regulates mainly adipocyte number rather than adipocyte size in vivo. The choice of appropriate species as experimental models is critical, especially for the study of PPARg.
The nuclear receptor peroxisome proliferator-activated receptor-g (PPARg) is a ligand-activated transcription factor that plays an important role as the master regulator for the development of adipocytes (1, 2) . PPARg binds to DNA as an obligate heterodimer with the retinoid X receptor and regulates expression of a number of genes related to adipocyte differentiation. The thiazolidinedione (TZD) class of antidiabetic drugs has been shown to be potent in selective ligands for PPARg (3) . Two TZDs, rosiglitazone and pioglitazone, are widely used for the treatment of type 2 diabetes. TZDs are believed to improve insulin sensitivity through the activation of PPARg. However, the precise mechanism that links PPARg activity with insulin sensitivity still remains unclear. One of the main reasons for this is that studies using mouse genetic models have shown unexpected phenotypes compared with in vitro experiments and the effect of TZDs in human (4) (5) (6) (7) (8) (9) .
For the past 25 years, many investigators of medicine and biology have chosen to use mouse models because the technologies involving embryonic stem cells allowed the generation of knockout and knockin mice (10) . In 1994, PPARg was first identified as a central regulator of gene expression and differentiation in adipocytes (11) . Since, many in vivo physiological studies on the role of PPARg in the regulation of adipogenesis and insulin sensitivity have been done mainly with mouse models (4) (5) (6) (7) (8) (9) (12) (13) (14) (15) . However, the results from experiments with mouse genetic models have been inconsistent with human evidence. Although TZDs increase adipocyte differentiation and insulin sensitivity in human (16) and patients with heterozygous PPARg dominant-negative mutation develop partial lipodystrophy and insulin resistance (17, 18) , heterozygous PPARg knockout mice (Pparg +/-) have increased insulin sensitivity, and mice with heterozygous PPARg dominant-negative mutation have normal insulin sensitivity and improved glucose tolerance (4) (5) (6) (7) . On the other hand, rats have a long history in medical research, being fundamental to drug development and advances of physiology and neuroscience. Rats are considered a better model than mice in their physiological and behavioral characteristics, which are sometimes more relevant to humans (19, 20) . In the current study, we used the N-ethyl-N-nitrosourea (ENU) mutagenesis method (21) to generate a heterozygous PPARg mutant (Pparg mkyo/+ ) rat. Pparg mkyo is a missense mutation located in the DNA binding domain that results in a complete loss of function for PPARg transcriptional activity with no dominantnegative activity against wild-type (WT) PPARg. Therefore, Pparg mkyo/+ rat is a de facto PPARg haploinsufficient model. Through the analysis of Pparg mkyo/+ rats, this study demonstrates anew that PPARg positively regulates fat mass and insulin sensitivity. It also reveals that the unexpected phenotypes of mouse models on PPARg are mouse specific. Furthermore, a novel finding of this study is that PPARg regulates mainly adipocyte number rather than adipocyte size in vivo. The study demonstrates that the choice of appropriate species as experimental models is critical and that Pparg mkyo/+ rats are useful for the study of PPARg.
RESEARCH DESIGN AND METHODS

Animals
Rats with a Pparg mutation were obtained by ENU mutagenesis of F344/NSlc rats followed by Mu Transposition Pooling Method With Sequencer (MuT-POWER) screening on the genomic DNA of 4,608 G1 male offspring in Kyoto University Rat Mutant Archive (KURMA). ENU mutagenesis procedures, screening protocols (21) , and the intracytoplasmic sperm injection procedure were previously described (22) . More than six backcross generations were performed against the F344/NSlc inbred background. Genotyping for Pparg mkyo mutation was performed by real-time PCR by using a TaqMan Sample-to-SNP kit (Applied Biosystems, Carlsbad, CA) with a specific primer pair (forward primer sequence 59-CTGTCGGATC CACAAAAAGAGTAGA-39 and reverse primer sequence 59-CCCCACAGCAAGGCACTT-39) and TaqMan MGB Probes (WT probe sequence 59-CTGAAACCGACAGTACTG-39 and mutant probe sequence 59-CTGAAACCGAAAGTACTG-39). Genomic DNA was extracted from whole blood. The cycling conditions were 20 s at 95°C followed by 40 cycles of 3 s at 95°C and 20 s at 60°C. Rats were maintained on a 14-h light/10-h dark cycle (lights on 7:00 A.M., lights off 9:00 P.M.) and fed an ad libitum standard pellet diet (MF; Oriental Yeast, Tokyo, Japan). For high-fat diet loading, rats were fed an ad libitum high-fat pellet diet containing 20% weight for weight (wt/wt) protein, 20% wt/wt carbohydrate, and 60% wt/wt fat (D12492; Research Diets, New Brunswick, NJ) from the ages of 8-16 weeks. All animal care and experiments conformed to the Guidelines for Animal Experiments at Kyoto University and were approved by the Animal Research Committee of Kyoto University.
Plasmid Construction, Transfection, and Luciferase Assay Full-length rat WT PPARg2 and its C193F mutant cDNA coding sequences were isolated from epididymal adipose tissue total RNA of WT and Pparg mkyo/+ rats, respectively, by RT-PCR using SuperScript III Reverse Transcriptase kit (Thermo Fisher Scientific, Waltham, MA) and Pfu DNA polymerase (Promega, Madison, WI). The WT PPARg2 and its C193F mutant cDNA fragments were cloned into the pTARGET Mammalian Expression Vector System (Promega) to give pTARGET-WT PPARg2 and pTARGET-C193F PPARg2 constructs, respectively. Luciferase assays were performed with a Cignal PPAR Reporter (luc) Kit (QIAGEN) according to the manufacture's protocol. Briefly, to investigate the effect of C193F mutation on PPARg2 transcriptional activity, pTARGET empty vector, pTARGET-WT PPARg2, or pTARGET-C193F PPARg2 was cotransfected with a mixture of PPAR-responsive firefly luciferase reporter and constitutively expressing Renilla construct to human embryonic kidney 293 cells by using Attractene Transfection Reagent (QIAGEN). To investigate the dominant-negative effect of C193F mutant against WT PPARg2, pTARGET-WT PPARg2 and pTARGET empty vector or pTARGET-C193F PPARg2 were cotransfected with reporter mixture. After transfection, cells were incubated at 37°C in a 5% CO 2 incubator for 24 h. The medium was then changed to DMEM containing 10% FBS. After 30 h of transfection, cells were treated with 10 mmol/L pioglitazone (Takeda Pharmaceutical Co., Ltd., Osaka, Japan) or vehicle. After 8 h of treatment, cells were harvested for luciferase assay (Dual-Luciferase Reporter Assay System; Promega).
Chromatin Immunoprecipitation Assay
The 3xFLAG tag DNA fragment was cloned into pTARGET-WT PPARg2 and pTARGET-C193F PPARg2 to give pTARGET-3xFLAG-WT PPARg2 and pTARGET-3xFLAG-C193F PPARg2. Human embryonic kidney 293 cells were transfected with pTARGET empty vector, pTARGET3xFLAG-WT PPARg2, or pTARGET-3xFLAG-C193F PPARg2 using Lipofectamine reagent (Thermo Fisher Scientific) and were treated with 10 mmol/L pioglitazone for 6 h. Soluble chromatin was immunoprecipitated with anti-FLAG mouse antibody (Merck Millipore, Etobicoke, ON, Canada).
Immunoprecipitates were subjected to quantitative real-time PCR with primer pairs specific to human lipoprotein lipase (LPL) and human perilipin 2 (PLIN2) promoters using KOD SYBR qPCR Mix (TOYOBO CO., LTD, Tokyo, Japan) (LPL promoter forward 59-GAAAACAGGTGATTGTTGAGT-39 and reverse 59-AACGTTTGAGCAAACA-39; PLIN2 promoter forward 59-GCAAAAAGAAGCTTGCTCAG-39 and reverse 59-TGTTGCCATCTTCAGTGTTT-39). Quantitative real-time PCR was also performed with the total chromatin input.
Whole-Body Composition Analysis
Sixteen-week-old rats under anesthesia were scanned from nose to anus by computed tomography (CT) with La Theta LCT-100 (Aloka, Tokyo, Japan). The X-ray source tube voltage was set at 50 kV with a constant 1-mA current. Aloka software estimated the volume of adipose tissue, bone, air, and the remainder by using differences in X-ray density. Distinguishing intra-abdominal adipose tissue and subcutaneous adipose tissue was based on detection of the abdominal muscle layers. Fat weight was calculated by using the commonly used density factor of 0.92 g/cm 3 . This method provides an accurate estimation of total subcutaneous and intra-abdominal fat pads, as validated by dissection (23) .
Adipose Tissue Histology and Adipocyte Size Measurement
Subcutaneous (inguinal), epididymal, and mesenteric fats were sampled from 16-week-old rats, fixed in 10% neutrally buffered formalin, and embedded in paraffin. Histological sections of 5-mm thickness were stained with hematoxylin and eosin and examined by light microscopy. Adipocyte size was evaluated in six rats from each group and six random fields (magnification 3100) per rat. To measure crosssectional adipocyte area, micrographs were taken with a fluorescent microscope (BioRevo BZ-9000; KEYENCE, Osaka, Japan) and analyzed with Dynamic Cell Count software (KEYENCE).
Liver Histology
Livers were sampled from 16-week-old rats, fixed in 10% neutrally buffered formalin, and embedded in paraffin. Histological sections of 5-mm thickness were stained with hematoxylin and eosin and examined by light microscopy.
Biochemical Assays
Blood was obtained from the tail vein after overnight fasting at the age of 16 weeks. Plasma leptin concentrations were measured by ELISA kit for rat leptin (Millipore, St. Charles, MO). Plasma glucose concentrations were measured by a glucose assay kit (Wako Pure Chemical Industries, Osaka, Japan). Plasma insulin concentrations were measured by an insulin-ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan). Plasma triglyceride (TG), nonesterified fatty acid (NEFA), and total cholesterol concentrations were measured by enzymatic kits (Triglyceride E-test Wako, NEFA C-test Wako,
and Cholesterol E-test Wako, respectively; Wako Pure Chemical Industries). To measure liver and skeletal muscle TG content, we sampled livers and gastrocnemius muscles from 16-week-old rats and immediately froze them in liquid nitrogen. Lipids were extracted with isopropyl alcoholheptane (1:1 volume for volume). After evaporating the solvent, we resuspended lipids in 99.5% volume for volume ethanol, and TG content was measured by an enzymatic kit (Triglyceride E-test Wako).
Calculation of HOMA of Insulin Resistance
The HOMA of insulin resistance (HOMA-IR) was calculated as an indicator of insulin sensitivity according to Eq. 1:
insulin ðmIU=mLÞ 3 glucose ðmg=dLÞ=405 ðEq: 1Þ
Glucose and Insulin Tolerance Tests
Intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (IPITT) were performed after overnight fasting in 16-week-old male rats. For the IPGTT, rats received 2.0 g/kg glucose, and blood was sampled from the tail vein before and 30, 60, and 120 min after the glucose load. For the IPITT, rats received 0.75 IU/kg insulin (Humulin R; Eli Lilly, Indianapolis, IN) by intraperitoneal injection. Blood was sampled from the tail vein before and 30, 60, and 90 min after the insulin load.
Pioglitazone Treatment
Pioglitazone (Wako Pure Chemical Industries) was dissolved in 0.01% carboxymethyl cellulose and administered at doses of 3 mg/kg by oral gavage (0.7 mL) once daily for 8 weeks from the age of 8 weeks in male Pparg mkyo/+ rats. For vehicle-control animals, the same amount of 0.01% carboxymethyl cellulose was administered.
Real-Time Quantitative RT-PCR
After sampling, tissues were immediately frozen in liquid nitrogen and stored at 280°C until use for RNA isolation. RNA was prepared using TRIzol reagent (Thermo Fisher Scientific) following the manufacturer's protocol. The quality and concentrations of the extracted RNA were checked by using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). Single-stranded cDNA was synthesized from 1 mg of total RNA with the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific) for RT-PCR according to the manufacturer's instructions. Quantitative RT-PCR was performed with TaqMan (Applied Biosystems) for housekeeping rat mitochondrial subunit 18S rRNA and rat Pparg and with SYBR Green (Applied Biosystems) for rat Fsp27 by the StepOnePlus Real-Time PCR System (Applied Biosystems). The sequences of primers and probe used were as follows: rat 18S forward 59-GCAATTATTCCCCATGAACGA-39, rat 18S reverse 59-CAAAGGGCAGGGACTTAATCAAC-39, probe 59-AATTCCCAGTAAGTGCGGGTCATAAGCTTG-39; rat Pparg forward 59-CCTGCGGAAGCCCTTTGGTGACT-39, rat Pparg reverse 59-TGACCAGGGAGTTCCTCAAAA-39, probe 59-AG CAAACTCAAACTTAGGCTCCAT-39; and rat Fsp27 forward 59-GTCTCTCAGCCTTCTCTACCC-39, rat Fsp27 reverse 59-CTTGCGCTGTTCTGATGGGG-39.
Statistical Analysis
Data are expressed as mean 6 SEM. Comparison between or among groups was assessed by Student t test or ANOVA with Fisher protected least significant difference test. P , 0.05 was considered statistically significant.
RESULTS
Generation of PPARg Mutant Rat and Functional Analysis of Its Mutation
By using ENU mutagenesis followed by MuT-POWER screening of the KURMA samples (21), we generated a heterozygous PPARg mutant (Pparg mkyo/+ ) rat with a missense mutation in Pparg. This Pparg mkyo mutation, which was G to T transition at nucleotide 488 for PPARg1 or 578 for PPARg2, resulted in a substitution of cysteine at codon 163 for PPARg1 or 193 for PPARg2 by phenylalanine (C163F or C193F), which is located in the DNA binding domain (Fig.  1A) . When male and female Pparg mkyo/+ rats were intercrossed, WT and Pparg mkyo/+ rats were obtained by a ratio of ;1:2, whereas no homozygous Pparg mkyo/mkyo rat was obtained. This result suggests that the Pparg mkyo/mkyo mutation was embryonic lethal and that the Pparg mkyo mutation had at least some effect on PPARg function. To investigate the effect of Pparg mkyo (C193F) mutation on PPARg2 transcriptional activity, we performed a luciferase reporter assay (Fig. 1B and C) . Compared with WT PPARg2, for which the transcriptional activity was appreciably detected at baseline and markedly increased by pioglitazone treatment, the C193F mutant had no significant transcriptional activity with or without pioglitazone, demonstrating that C193F is a complete loss-of-function mutation (Fig. 1B) . Furthermore, the transcriptional activity of WT PPARg2 was not affected by the presence of the C193F mutant with or without pioglitazone, demonstrating that the C193F mutant has no dominant-negative activity against WT PPARg2 (Fig. 1C) . Because the C193F mutation is located in the DNA binding domain of PPARg, the effect of C193F . Arrows indicate the amino acid position of the C163F mutation in PPARg1 and the C193F mutation in PPARg2. B and C: Luciferase assays for the effect of C193F mutation on PPARg2 transcriptional activity (B) and for the dominant-negative effect of C193F mutant against WT PPARg2 (C) with or without pioglitazone (Pio). In these panels, vector indicates pTARGET empty vector; WT, pTARGET-WT PPARg2 vector; and C193F, pTARGET-C193F mutant PPARg2 vector. Data are mean 6 SEM of three independent experiments. Values obtained with WT PPARg2 vector (B) or WT PPARg2 vector and empty vector (C) without pioglitazone are defined as 1.0. D and E: Chromatin immunoprecipitation assays for the effect of C193F mutation on PPARg2 binding on the LPL promoter and PLIN2 promoter. In these panels, vector indicates pTARGET empty vector; WT, pTARGET-3xFLAG-WT PPARg2 vector; and C193F, pTARGET-3xFLAG-C193F mutant PPARg2 vector. Soluble chromatin was immunoprecipitated with anti-FLAG mouse antibody. Data are percentage of total chromatin input and mean 6 SEM of three independent experiments. **P < 0.01 by Student t test. NS, not significant. mutation on PPARg2 binding on LPL and PLIN2 promoters, including PPARg-responsive element, was investigated by chromatin immunoprecipitation assay ( Fig. 1D and E). Although binding on both LPL and PLIN2 promoters was observed with WT PPARg2, no significant binding was detected with C193F PPARg2 on these promoters compared with results from the empty vector. At this time, WT PPARg2 and C193F mutant proteins were equally expressed, indicating that C193F mutation does not destabilize the protein (Supplementary Fig. 1 ). These findings demonstrate that the C193F mutation impairs the DNA binding ability of PPARg. No difference in gross appearance between male and female WT and Pparg mkyo/+ rats fed the standard diet was detected ( Fig. 2A) . Body weight was also unchanged between these groups from birth to age 16 weeks (Fig. 2B  and C) . Thus, we fed male and female rats a high-fat diet from the age of 8 weeks. Although the high-fat diet increased body weight in both WT and Pparg mkyo/+ rats, there was still no significant difference between either group ( Fig. 2D and Supplementary Fig. 2A ). Food intake was also unchanged between WT and Pparg mkyo/+ rats fed the standard and high-fat diets (Fig. 2E and Supplementary Fig. 2B ). In addition, no difference of plasma leptin concentration, an indicator of total body fat, was observed with both the standard and the high-fat diets (Fig. 2F) . Whole-body CT scan was performed to evaluate adiposity in male and female Pparg mkyo/+ rats. All subcutaneous and intra-abdominal fat weights in Pparg mkyo/+ rats were slightly, but significantly lower than in WT rats fed the standard diet (Fig. 3A-C and Supplementary Fig. 3A-C) . However, all these differences between WT and Pparg mkyo/+ rats disappeared with the high-fat diet (Fig. 3A-C and Supplementary Fig. 3A-C) . Weights of epididymal and mesenteric fats, which are the structural components of intra-abdominal fat, were measured directly in both male and female rats. Epididymal fat weight in Pparg mkyo/+ rats was lower than in WT rats fed the standard and high-fat diets ( Fig. 3D and Supplementary Fig. 3D ). On the other hand, no significant difference was found in mesenteric fat weight between WT and Pparg mkyo/+ rats fed the standard and the high-fat diets ( Fig. 3E and Supplementary  Fig. 3E ). These results suggest that some difference is present in the effect of PPARg haploinsufficiency between fat tissues.
Adipocyte Size in Pparg mkyo/+ Rats Subcutaneous, epididymal, and mesenteric fats were histologically examined in both male and female rats ( and Supplementary Fig. 4A ). In males, although there was no significant difference in mean cross-sectional adipocyte area of subcutaneous fat between WT and Pparg mkyo/+ rats fed the standard diet (Fig. 4B) , that of epididymal and mesenteric fats in Pparg mkyo/+ rats was significantly larger than in WT rats fed the standard diet ( Fig. 4C and D) . With the high-fat diet, mean cross-sectional adipocyte area of all these fats in Pparg mkyo/+ rats were larger than in WT rats (Fig. 4B-D) . In female rats, adipocyte area of all fats in Pparg mkyo/+ rats were significantly larger than in WT rats fed the standard and high-fat diets ( Supplementary  Fig. 4B-D) . Even with the standard diet, in all subcutaneous, epididymal, and mesenteric fats, large adipocytes not present in WT rats were observed in Pparg mkyo/+ rats, and adipocyte size distribution deviated to the right in Pparg mkyo/+ rats compared with WT rats (Fig. 4E ). These deviations were more evident with the high-fat diet (Fig. 4E) .
Induction of Adipocyte Differentiation in Rat Dermal Fibroblasts From Pparg mkyo/+ Rats
To investigate the effect of PPARg haploinsufficiency in adipocyte differentiation, we stimulated adipocyte differentiation in rat dermal fibroblasts (RDFs) from WT and Pparg mkyo/+ rats. Oil red O staining showed that the number of differentiated adipocytes in Pparg mkyo/+ RDFs was lower than that in WT RDFs (Supplementary Fig. 5 ). However, pioglitazone treatment increased the number of differentiated adipocytes in both WT and Pparg mkyo/+ RDFs, and the difference disappeared ( Supplementary  Fig. 5 ).
Phenotypes of Liver and Skeletal Muscle in Pparg mkyo/+
Rats
Although no difference in histological images of the liver between WT and Pparg mkyo/+ rats was detected with the standard diet, lipid droplets were more noticeable in Pparg mkyo/+ rats than in WT rats fed the high-fat diet (Fig. 5A) . Consistent with this, no significant difference in liver weight was found between WT and Pparg mkyo/+ rats fed the standard diet, but Pparg mkyo/+ rat livers were significantly heavier than those of WT rats fed the high-fat diet ( Fig. 5B and Supplementary Fig. 6A ). Liver TG content was significantly higher in Pparg mkyo/+ rats, even with the standard diet, and this difference of liver TG content was more evident with the high-fat diet ( Fig.  5C and Supplementary Fig. 6B ). Total muscle weight was measured by whole-body CT scan. Although there was no significant difference in total muscle weight between WT and Pparg mkyo/+ rats fed the standard diet, that in Pparg mkyo/+ rats was slightly, but significantly heavier than in WT rats fed the high-fat diet (Fig. 5D and Supplementary Fig. 6C ). Gastrocnemius muscle TG content also showed no significant difference with the standard diet but was higher in Pparg mkyo/+ rats than in WT rats ( Fig. 5E and Supplementary Fig. 6D ).
Glucose and Lipid Metabolism in Pparg mkyo/+ Rats
There was no significant difference in fasting glucose concentration between WT and Pparg mkyo/+ rats fed the standard and high-fat diets ( Fig. 6A and Supplementary  Fig. 7A ). However, fasting insulin concentration was significantly higher in Pparg mkyo/+ rats than in WT rats fed Figure 3 -Site-specific fat weight in male Pparg mkyo/+ rats and their WT littermates fed a standard diet (SD) or high-fat diet (HFD). A-C: Weight of total fat, subcutaneous fat, and intra-abdominal fat measured by whole-body CT scan. D and E: Weight of epididymal fat and mesenteric fat measured directly. Data are mean 6 SEM (n = 10/group). *P < 0.05, **P < 0.01 by Student t test. NS, not significant. the high-fat diet, whereas no significant difference was found with the standard diet ( Fig. 6B and Supplementary  Fig. 7B ). As a result, HOMA-IR, an indicator of insulin resistance, was significantly higher in Pparg mkyo/+ rats than in WT rats fed the high-fat diet (Fig. 6C) . Glucose tolerance examined by IPGTT was worse in Pparg mkyo/+ rats, Figure 4 -Site-specific adipocyte mean size and size distribution in male Pparg mkyo/+ rats and their WT littermates fed a standard diet (SD) or high-fat diet (HFD). A: Histological images of subcutaneous (inguinal), epididymal, and mesenteric fats. For histological examination, hematoxylin and eosin staining was used (original magnification 3100). B-D: Mean cross-sectional area of adipocytes in subcutaneous (inguinal), epididymal, and mesenteric fats. Data are mean 6 SEM (n = 10/group). E: Adipocyte size distribution in subcutaneous (inguinal), epididymal, and mesenteric fats. **P < 0.01 by Student t test. NS, not significant. even on the standard diet, and this exacerbation was more evident with the high-fat diet (Fig. 6D) . Although no significant exacerbation in insulin sensitivity examined by IPITT was detected in Pparg mkyo/+ rats fed the standard diet, insulin resistance was observed in Pparg mkyo/+ rats fed the high-fat diet (Fig. 6E) . Insulin-induced phosphorylation of insulin receptor substrate 1 and Akt was decreased not only in adipose tissues, including subcutaneous, epididymal, and mesenteric fats, but also in liver and skeletal muscle in Pparg mkyo/+ rats fed the high-fat diet (Supplementary Fig. 8 ). As to lipid metabolism, no significant difference was found in all plasma TG, NEFA, and total cholesterol concentrations between WT and Pparg mkyo/+ rats fed the standard and high-fat diets (Fig. 7A-C and Supplementary  Fig. 7C ).
Phenotypes of Brown Adipose Tissue in Pparg mkyo/+
Rats
No difference in gross appearance of interscapular brown adipose tissue (BAT) between WT and Pparg mkyo/+ rats was detected ( Supplementary Fig. 9A ). BAT weight was also unchanged between WT and Pparg mkyo/+ rats at baseline (Supplementary Fig. 9C ). To examine the physiological function of BAT, we conducted a cold exposure experiment. There was no difference in body temperature between WT and Pparg mkyo/+ rats at baseline ( Supplementary   Fig. 9B ). Although 24-h exposure of 4°C decreased the body temperature in both, no difference in body temperature was observed between WT and Pparg mkyo/+ rats after cold exposure (Supplementary Fig. 9B ). At this time, BAT weight was similarly decreased in WT and Pparg mkyo/+ rats ( Supplementary Fig. 9C ). Histological analysis revealed the reduction of lipid content by cold exposure in both WT and Pparg mkyo/+ rats ( Supplementary Fig. 9D ). In addition, increment of Ucp1 mRNA expression by cold exposure was similarly observed in these rats (Supplementary Fig. 9E ). These results indicate that PPARg haploinsufficiency has little effect on the physiological function of BAT.
Pioglitazone Treatment in Pparg mkyo/+ Rats
To investigate whether TZD, an agonist of PPARg can rescue the phenotypes of Pparg mkyo/+ rats, we treated Pparg mkyo/+ rats fed the high-fat diet with pioglitazone for 8 weeks. Pioglitazone treatment increased body weight in these rats ( Supplementary Fig. 10A ), and we observed a nonsignificant tendency toward incremental food intake ( Supplementary Fig. 10B ). Total, subcutaneous, and intraabdominal fat weights measured by CT scan were increased by pioglitazone treatment (Supplementary Fig. 11A-C) . In direct measurement, epididymal fat weight was also increased, whereas mesenteric fat weight showed no significant increment by pioglitazone treatment (Supplementary For histological examination, hematoxylin and eosin staining was used (original magnification 3100). Liver weight (B), liver TG content (C), and total muscle weight (D) measured by whole-body CT scan and TG content in gastrocnemius muscle (E). Data are mean 6 SEM (n = 10/group). *P < 0.05, **P < 0.01 by Student t test. NS, not significant. Fig. 11D and E) . In histological examination (Supplementary Fig. 12A ), pioglitazone treatment slightly, but significantly decreased adipocyte area in subcutaneous fat, whereas that in epididymal and mesenteric fats was unchanged ( Supplementary Fig. 12B-D) . Pioglitazone treatment did not affect liver weight and the total muscle weight measured by CT scan but significantly decreased TG content in the liver and skeletal muscle (Supplementary Fig. 13 ). Pioglitazone treatment significantly decreased fasting glucose and insulin concentrations, indicating that pioglitazone treatment effectively increased insulin sensitivity in Pparg mkyo/+ rats (Supplementary Fig. 14A and B) . Pioglitazone treatment also decreased fasting TG concentration in Pparg mkyo/+ rats ( Supplementary  Fig. 14C ).
Pparg and Fsp27 mRNA Expression in Fat Tissues in Pparg mkyo/+ Rats
To investigate the molecular mechanism by which PPARg haploinsufficiency affects the phenotype, we examined Figure 6 -Glucose metabolism in male Pparg mkyo/+ rats and their WT littermates fed a standard diet (SD) or high-fat diet (HFD). A-C: Fasting plasma glucose, fasting plasma insulin concentration, and HOMA-IR. Data are mean 6 SEM (n = 10/group). *P < 0.05, **P < 0.01 by Student t test. D and E: Plasma glucose concentrations during IPGTT and IPITT. ○, WT rats fed SD; •, Pparg mkyo/+ rats fed SD; □, WT rats fed HFD; ■, Pparg mkyo/+ rats fed HFD. Data are mean 6 SEM (n = 10/group). *P < 0.05, **P < 0.01 vs. WT rats fed HFD (ANOVA); †P < 0.05 vs. WT rats fed SD (ANOVA). NS, not significant. mRNA expression of PPARg and its target genes that have the PPARg responsive element in their promoter, and their expression is regulated by PPARg in fat tissues, liver, and skeletal muscle in Pparg mkyo/+ rats ( Fig. 8 and Supplementary Figs. 15 and 16 ). With the standard diet, no significant difference was found in mRNA expression of Pparg and its target genes, including Fsp27, Adipoq, Cd36, Fabp4, and Plin1 between WT and Pparg mkyo/+ rats in any fat tissues (Fig. 8 and Supplementary Figs. 15 and 16) . The high-fat diet significantly increased mRNA expression of both Pparg and its target genes in all fat tissues in WT rats but did not increase either in any fat tissues in Pparg mkyo/+ rats ( Fig. 8 and Supplementary Figs. 15 and  16 ). Pioglitazone treatment effectively increased mRNA expression of both Pparg and its target genes in all fat tissues in Pparg mkyo/+ rats fed the high-fat diet ( Fig. 8 and Supplementary Figs. 15 and 16 ). On the other hand, no significant difference was found in mRNA expressions of Pparg and its target genes, including Fsp27 and Cd36, in liver and skeletal muscle between WT and Pparg mkyo/+ rats fed the standard and high-fat diets ( Supplementary Fig. 16 ). Pioglitazone treatment did not increase these mRNA expressions in liver and skeletal muscle (Supplementary Fig. 16 ).
DISCUSSION
Using gene-driven ENU mutagenesis, we generated a heterozygous PPARg mutant (Pparg mkyo/+ ) rat. Pparg mkyo is a missense mutation (C163F for PPARg1 and C193F for PPARg2) located in the DNA binding domain (Fig. 1A) . Luciferase reporter assay revealed that Pparg mkyo is a complete loss-of-function mutation at least for its transcriptional activity. Chromatin immunoprecipitation assay revealed that the C193F mutation impaired the DNA binding of PPARg. When male and female Pparg mkyo/+ rats were intercrossed, no homozygous Pparg mkyo/mkyo rat was obtained, whereas WT and Pparg mkyo/+ rats were obtained by the expected ;1:2 Mendelian ratio of genotypes. This result suggests that homozygous Pparg mkyo/mkyo rat is embryonic lethal. It was previously reported that homozygous PPARg knockout mouse is embryonic lethal due to placental dysfunction (4), which supports the notion that Pparg mkyo is a loss-of-function mutation also in vivo. Furthermore, luciferase reporter assay revealed that the Pparg mkyo mutant has no dominant-negative activity against WT PPARg. Therefore, Pparg mkyo/+ rat is a de facto PPARg haploinsufficient model like the Pparg +/-mouse. The mean mutation frequency with ENU mutagenesis of our protocol was one mutation per 3.7 million base pairs (21) . Although the chance for the occurrence of an unexpected mutation with a phenotypic effect is relatively small, this possibility also should be taken into account for the experimental design and interpretation of the results. To eliminate mutations that might have been generated by ENU mutagenesis in chromosomal regions other than the Pparg locus, we performed a backcross of Pparg mkyo/+ rats fed HFD were treated with pioglitazone (Pio) or vehicle. mRNA expression levels were normalized by 18S rRNA. The fold change is relative to WT rats fed SD. Data are mean 6 SEM (n = 5/group). **P < 0.01 by Student t test. NS, not significant. more than six generations against an F344/NSlc inbred background, and we always compared phenotypes between littermates to minimize the effect of possible unexpected mutations.
In this study, the weight of epididymal and mesenteric fats were measured directly. Although epididymal fat weight was reduced, mesenteric fat weight was unchanged in Pparg mkyo/+ rats compared with WT rats fed both standard and high-fat diets (Fig. 3D and E and Supplementary Fig. 3D and E) . In patients with familial partial lipodystrophy type 3 (FPLD3, Mendelian Inheritance in Man 604367) that results from heterozygous mutation in PPARG, subcutaneous fat mass is reduced, especially in the extremities, whereas intra-abdominal fat mass is preserved (24, 25) . Consistent with this, treatment with PPARg agonist TZDs generally increases subcutaneous fat mass but decreases intra-abdominal fat mass (26, 27) . These observations indicate that the effect of PPARg on adiposity varies with location of fat.
Pparg mkyo/+ rats fed both standard and high-fat diets showed adipocyte hypertrophy in subcutaneous, epididymal, and mesenteric fats (Fig. 4 and Supplementary  Fig. 4 ). Although no statistically significant difference of mean adipocyte area in subcutaneous fat of male Pparg mkyo/+ rats fed a standard diet (Fig. 4B) was found, larger adipocytes were detected in subcutaneous fat of male Pparg mkyo/+ rats, even with a standard diet (Fig. 4E) . Considering adipocyte hypertrophy with the observation that fat mass was reduced or unchanged in Pparg mkyo/+ rats, adipocyte number was decreased in Pparg mkyo/+ rats in all fats examined in this study regardless of diet. The adipocyte hypertrophy observed in Pparg mkyo/+ rats may be a compensatory response to the decrease in adipocyte number. Treatment with TZDs increases fat mass but decreases mean adipocyte size in human (16) , indicating that TZDs increase adipocyte number in human. In the current study, pioglitazone treatment increased fat mass but decreased or did not change adipocyte area in Pparg mkyo/+ rats ( Supplementary Figs.  11 and 12 ), indicating that pioglitazone treatment increased adipocyte number in rat. Taken together, PPARg positively regulates adipocyte number in both rat and human.
To investigate the molecular mechanism by which PPARg haploinsufficiency affects the phenotype of fat tissues, we examined mRNA expression of PPARg and its target genes in fat tissue, liver, and skeletal muscle in Pparg mkyo/+ rats ( Fig. 8 and Supplementary Figs. 15 and  16 ). Because the method for analyzing Pparg mRNA expression did not discriminate mutant mRNA from WT mRNA, no significant difference was found in Pparg mRNA expression between WT and Pparg mkyo/+ rats fed a standard diet. For PPARg target genes, we selected Fsp27, Adipoq, Cd36, Fabp4, and Plin1, which have a PPARg responsive element in their promoter and in which expression is regulated by PPARg. The high-fat diet significantly increased mRNA expression of PPARg target genes in fat tissues in WT rats but did not in Pparg mkyo/+ rats. Pioglitazone treatment increased mRNA expression of PPARg target genes in fat tissues even in Pparg mkyo/+ rats. These observations indicate that the reduction of PPARg transcriptional activity in fat tissues contribute to the phenotype observed in Pparg mkyo/+ rats and that pioglitazone treatment rescued the phenotype by increasing PPARg transcriptional activity in fat tissue. On the other hand, neither PPARg haploinsufficiency nor pioglitazone treatment affected mRNA expression of PPARg target genes in liver and skeletal muscle, indicating that liver and muscle are not main sites of PPARg action in rats.
With the high-fat diet, liver and skeletal muscle TG content was markedly increased in Pparg mkyo/+ rats compared with WT rats (Fig. 5 and Supplementary Fig. 6 ) but was not explained by only energy balance because no difference in food intake and total fat mass between WT and Pparg mkyo/+ rats was found. On the high-fat diet, Pparg mkyo/+ rats had apparent insulin resistance and hyperinsulinemia ( Fig. 6 and Supplementary Fig. 7) ; thus, hyperinsulinemia possibly contributed to the increase of liver and muscle TG content in Pparg mkyo/+ rats fed a high-fat diet. Indeed, pioglitazone treatment increased insulin sensitivity and decreased liver and muscle TG content in Pparg mkyo/+ rats ( Supplementary Figs. 13 and 14) .
With the standard diet, although there was no statistically significant difference of serum insulin level or HOMA-IR between WT and Pparg mkyo/+ rats ( Fig. 6 and Supplementary Fig. 7 ), Pparg mkyo/+ rats showed glucose intolerance by IPGTT compared with WT rats (Fig. 6) . With the high-fat diet, Pparg mkyo/+ rats had significantly increased serum insulin levels, HOMA-IR, and insulin resistance by IPITT ( Fig. 6 and Supplementary Fig. 7 ). Patients with FPLD3, which results from a heterozygous mutation in PPARG, show insulin resistance regardless of whether mutations have dominant-negative activity (17, 18) . These observations indicate that PPARg haploinsufficiency commonly causes insulin resistance in rat and human. In contrast to PPARg haploinsufficiency, treatment with TZDs increases adipocyte number and decreases mean adipocyte size (16) . In the current study, pioglitazone treatment also increased adipocyte number and insulin sensitivity in Pparg mkyo/+ rats. The deleterious effect of PPARg haploinsufficiency on insulin sensitivity might be associated with limited adipocyte number and adipocyte hypertrophy.
Inconsistent with rat and human, it was reported that Pparg +/2 mice had increased insulin sensitivity (4, 5) , and mice with a heterozygous PPARg dominant-negative mutation (Pparg P465L/+ ) had normal insulin sensitivity and improved glucose tolerance (6) . In Pparg +/2 mice, although fat mass was reduced like in rat and human, adipocyte size was decreased unlike in rat and human (4) . Despite fat mass reduction, Pparg +/2 mice had hyperleptinemia, which led to suppression of food intake and elevation of body temperature, an index of energy expenditure (4). The negative energy balance brought by hyperleptinemia might keep adipocyte size small. As a result, Pparg +/2 mice showed increased insulin sensitivity. In Pparg P465L/+ mice, although adipocyte size was increased like in rat, subcutaneous fat mass was increased unlike in rat and human (6) . Pparg P465L/+ mice had hyperinsulinemia, which might modify the adiposity and keep insulin sensitivity normal (6) . The mechanisms by which Pparg +/2 mice had hyperleptinemia and Pparg P465L/+ mice had hyperinsulinemia are unknown, but in mouse, PPARg plays unexpected physiological roles not observed in rat and human.
In conclusion, this study demonstrates that PPARg haploinsufficiency causes fat mass reduction, adipocyte hypertrophy, and insulin resistance, which are consistent with the phenotype of patients with heterozygous PPARG mutation and the effect of PPARg agonist TZDs in human, and inconsistent with the phenotypes of Pparg +/-mice and heterozygous Pparg mutant mice. The choice of appropriate species as experimental models is critical, especially for the study of PPARg.
